NCT02414347

F 18 T807 Tau PET Imaging of Alzheimer's Disease

F 18 T807 Tau PET Imaging of Alzheimer's Disease [IND# 123119] Protocol A

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 900 (estimated)
• Sponsor: Tammie L. S. Benzinger, MD, PhD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A single-center, open-label baseline controlled imaging study designed to assess whether brain tau fibril uptake of flortaucipir as measured by PET correlates with cognitive status of individuals with and without brain tau fibrils.

Detailed description

This project will collect quantitative pilot data that will allow the characterization of uptake and binding of 18F-AV-1451 (also known as F 18 T807), a novel tau imaging compound, in individuals with and without brain tau fibrils. The primary goal is to develop tau imaging technique as an antecedent biomarker of cognitive decline. The investigators propose to obtain preliminary data that will support the possibility of detecting cognitive decline in its earliest stages, before the occurrence of dementia.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	F 18 T807	Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.

Timeline

• Start date: 2014-10-23
• Primary completion: 2024-10-01
• Completion: 2024-12-01
• First posted: 2015-04-10
• Last updated: 2024-07-17

Locations

1 site across 1 country: United States